No current standard human surrogate exists that focuses on non-lethal weapon (NLW) exposures; however CFD Research Corporation’s (CFDRC’s) modular human surrogate will solve that problem. The modular human surrogate is capable of measuring a wide variety of stimuli produced by NLWs to gauge performance, safety, and risk of significant injury (RSI) of NLWs. This system’s modular focus enables adaptability to current/future technologies with relatively small changes, low cost, and state-of-the-art sensors. The system has been prototyped and functionality verified for many NLW stimuli. CFDRC specializes in creating unique and valuable solutions to problems related to human body response and performance. Our goal is to transition this surrogate into government/prime contractors/developers of NLWs to become the testing standard used for demonstrating/evaluating human response and RSI due to NLWs.
Platelet products play an important role in treatment of hemorrhage patients. However, platelet products are unavailable at forward surgical facilities (Role 2) due to their short shelf life (3-5 days). CFD Research’s platelet apheresis platform will allow for collection of fresh leukocyte-reduced platelet products in expeditionary settings. The ruggedized system will enable Role 2 teams to utilize freshly donated platelets to broaden treatment options and improve outcomes for combat casualties. Proof-of-concept for the system has been established. Development of integrated prototype for field testing is ongoing. CFD Research develops cutting edge technologies and provides innovative solutions for Aerospace, Biomedical and other industries and has extensive experience in the development of biomedical devices. Our goal is to transition the technology into Role 2 surgical teams.